GlassScriptPhysician profile
Matthew E Krupnick
NPI 1629005566
$758.86
in general payments reported to CMS, 2019-2025
14 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.36 · 2021: $100 · 2022: $151 · 2023: $152 · 2024: $179 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449 · Education: $30.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.09 |
| Education | $30.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $137.27 | 2021-2024 | |
| Gilead Sciences, INC. | $114.68 | 2022-2024 | |
| Vivus LLC | $109.97 | 2022-2025 | Pancreaze, Qsymia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.94 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $78.45 | 2024-2025 | Voquezna |
| Omeros Corporation | $52.04 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $41.12 | 2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $28.01 | 2022-2025 | |
| Janssen Biotech, INC. | $27.19 | 2022-2024 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $16.19 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Celltrion USA INC. | $14.36 | 2024 | Zymfentra |
| Pfizer INC. | $13.38 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.15 | 2023 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Krupnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.